About

Biography

My early work with outstanding mentors, who were pediatric rheumatologists, led me to pursue my clinical and research interests. During my fellowship, the unfortunate death of a patient from macrophage activation syndrome (MAS) prompted me to further study this life-threatening complication of systemic juvenile idiopathic arthritis.

Currently, I focus on identifying risk factors and new therapeutic targets in MAS. Our transnational studies have identified interferon gamma (INF), a dimerized soluble cytokine, as a therapeutic target in patients suffering from MAS. This discovery provided the rationale for a new clinical trial that is currently underway.

My research is funded by the National Institutes of Health (NIH) and the Systemic Juvenile Idiopathic Arthritis (SJIA) Foundation. I have also received research grants from Sobi, Novartis and AB2Bio.

MD: Leningrad (St. Petersburg) Pediatric Medical Institute, Russia, 1986.

Residency: Leningrad (St. Petersburg) Medical Institute, Russia, 1988; Children's Hospital Medical Center, Cincinnati, OH, 1998.

Fellowship: Leningrad (St. Petersburg) Pediatric Medical Institute, Russia, 1991; Children's Hospital Medical Center, Cincinnati, OH, 1995.

Certification: Pediatrics, 1999.

Services and Specialties

Rheumatology, Lupus, Rare Lung Diseases

Research Areas

Rheumatology

Additional Languages

French, Russian

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Recombinant Interleukin-1 Receptor Antagonist Is an Effective First-Line Treatment Strategy in New-Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA-DRB1 Background and IL1RN Variants. Erkens, RG A; Calis, JJ A; Verwoerd, A; De Roock, S; Ter Haar, NM; Den Engelsman, G; Van der Veken, LT; Ernst, RF; Van Deutekom, HW M; Pickering, A; et al. Arthritis and Rheumatology. 2024; 76:119-129.

Population-level single-cell genomics reveals conserved gene programs in systemic juvenile idiopathic arthritis. Verweyen, EL; Thakkar, K; Dhakal, S; Baker, E; Chetal, K; Schnell, D; Canna, S; Grom, AA; Salomonis, N; Schulert, GS. The Journal of Clinical Investigation. 2023; 133:e166741.

Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease. Towe, C; Grom, AA; Schulert, GS. Pediatric Drugs. 2023; 25:649-658.

The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS). Shakoory, B; Geerlinks, A; Wilejto, M; Kernan, K; Hines, M; Romano, M; Piskin, D; Ravelli, A; Sinha, R; Aletaha, D; et al. Arthritis and Rheumatology. 2023; 75:1714-1732.

The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS). Shakoory, B; Geerlinks, A; Wilejto, M; Kernan, K; Hines, M; Romano, M; Piskin, D; Ravelli, A; Sinha, R; Aletaha, D; et al. Annals of the Rheumatic Diseases. 2023; 82:1271-1285.

OP0166 LONG-TERM FOLLOW-UP OF PATIENTS ADMINISTERED EMAPALUMAB, AN ANTI–INTERFERON-Γ MONOCLONAL ANTIBODY, TO TREAT MACROPHAGE ACTIVATION SYNDROME (MAS) SECONDARY TO SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). De Benedetti, F; Grom, A; Brogan, P; Bracaglia, C; Pardeo, M; Marucci, G; Eleftheriou, D; Papadopoulou, C; Schulert, G; Quartier, P; et al. 2023; 110-111.

Efficacy and safety of emapalumab in macrophage activation syndrome. De Benedetti, F; Grom, AA; Brogan, PA; Bracaglia, C; Pardeo, M; Marucci, G; Eleftheriou, D; Papadopoulou, C; Schulert, GS; Quartier, P; et al. Annals of the Rheumatic Diseases. 2023; 82:857-865.

Lung Ultrasound in Children With Systemic Juvenile Idiopathic Arthritis-Associated Interstitial Lung Disease. Vega-Fernandez, P; Ting, TV; Mar, DA; Schapiro, AH; Deluna, MD; Saper, VE; Grom, AA; Schulert, GS; Fairchild, RM. Arthritis Care and Research. 2023; 75:983-988.

Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis. Miraldi Utz, V; Angeles-Han, ST; Mwase, N; Cassedy, A; Hennard, T; Lovell, DJ; Lopper, S; Brunner, HI; Dosunmu, EO; Grom, AA; et al. American Journal of Ophthalmology. 2022; 244:183-195.

Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis. Chen, G; Deutsch, GH; Schulert, GS; Zheng, H; Jang, SR; Trapnell, B; Lee, PY; Macaubas, C; Ho, K; Schneider, C; et al. Arthritis and Rheumatology. 2022; 74:1271-1283.

From the Blog

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

4.6
Overall Patient Rating